Articles by Cynthia Challener, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Cynthia Challener, PhD

Plasmon Resonance Microscopy Enables Analysis of Molecular-Scale Phenomena in Living Systems

Plasmonic imaging overcomes the limitations of traditional microscopy and can be used for the analysis of single cells, cell organelles, viruses, and even single protein-protein interactions.
Oct 9, 2013

Plasmonic imaging overcomes the limitations of traditional microscopy and can be used for the analysis of single cells, cell organelles, viruses, and even single protein-protein interactions.

Leveraging Single-Use Learnings in Fill-Finish Operations

After realizing benefits from the adoption of a single-use filling line for one specific product, Patheon took the leap and installed a single-use filling line in a new facility.
Oct 9, 2013

After realizing benefits from the adoption of a single-use filling line for one specific product, Patheon took the leap and installed a single-use filling line in a new facility.

Sterile, Automated Sampling Enabling PAT for Biopharmaceutical Manufacturing

Pfizer, Eli Lilly, and several other pharmaceutical companies are participating in the development of automated sampling technology and associated software that improve process control and reduce development times in biopharmaceutical manufacturing.
Oct 9, 2013

Pfizer, Eli Lilly, and several other pharmaceutical companies are participating in the development of automated sampling technology and associated software that improve process control and reduce development times in biopharmaceutical manufacturing.

Exploring Single-Use Systems for Fill-Finish Operations

The need to develop a final formulation process for a parenteral product sensitive to stainless-steel gave Patheon the opportunity to evaluate the potential of single-use technology in fill-finish operations.
Oct 9, 2013

The need to develop a final formulation process for a parenteral product sensitive to stainless-steel gave Patheon the opportunity to evaluate the potential of single-use technology in fill-finish operations.

GlaxoSmithKline Adopts Continuous Manufacturing for Preparation of Key Intermediate

Use of a continuous-flow reaction made it possible to scale up a highly exothermic reaction for the production of a key Suzuki−Miyaura coupling reagent.
Oct 9, 2013

Use of a continuous-flow reaction made it possible to scale up a highly exothermic reaction for the production of a key Suzuki−Miyaura coupling reagent.

GlaxoSmithKline, Novartis, and AstraZeneca Fund Center Focused on Advancing Commercial-Scale Continuous Crystallization

Through partnerships and collaborations between academia, industry, and the public sector, the Center for Continuous Manufacturing and Crystallization is advancing continuous crystallization technologies.
Oct 9, 2013

Through partnerships and collaborations between academia, industry, and the public sector, the Center for Continuous Manufacturing and Crystallization is advancing continuous crystallization technologies.

GlaxoSmithKline Adopts Continuous Manufacturing for Preparation of Key Intermediate

Use of a continuous-flow reaction made it possible to scale up a highly exothermic reaction for the production of a key Suzuki−Miyaura coupling reagent.
Sep 25, 2013

Use of a continuous-flow reaction made it possible to scale up a highly exothermic reaction for the production of a key Suzuki−Miyaura coupling reagent.

Pfizer Applies Integrated Technology for Cell-Line Development of Proprietary Antibodies

Pfizer advances its pipeline of antibody-based therapies using a host cell line that combines engineered glycosylation technology and enhanced gene-expression.
Sep 25, 2013

Pfizer advances its pipeline of antibody-based therapies using a host cell line that combines engineered glycosylation technology and enhanced gene-expression.

Exploring Single-Use Systems for Fill-Finish Operations

The need to develop a final formulation process for a parenteral product sensitive to stainless-steel gave Patheon the opportunity to evaluate the potential of single-use technology in fill-finish operations.
Sep 25, 2013

The need to develop a final formulation process for a parenteral product sensitive to stainless-steel gave Patheon the opportunity to evaluate the potential of single-use technology in fill- finish operations.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
FindPharma Custom Search
Click here